Measurement of Retinal Nerves and Blood Vessels as Markers for Type 1 Diabetes

测量视网膜神经和血管作为 1 型糖尿病的标志物

• 批准号: 9754819
• 负责人: Mircea Mujat
• 金额: $ 50.47万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9754819
• 关键词: Affect; Axon; Biological Markers; Blood Vessels; Blood capillaries; Boston; Characteristics; Clinic; Clinical; Clinical Engineering; Clinical Management; Collaborations; Complex; Complications of Diabetes Mellitus; Data; Detection; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Diagnostic; Disease; Disease Marker; Disease Progression; Early Diagnosis; Evolution; Fiber Optics; Funding; Histopathology; Human Volunteers; Image; Imagery; Imaging Techniques; Imaging technology; Incidence; Insulin-Dependent Diabetes Mellitus; Knowledge; Laboratory Research; Lasers; Light; Market Research; Measurement; Medical; Metabolic; Modality; Monitor; Morphologic artifacts; Morphology; Nerve; Nerve Fibers; Neurons; Ophthalmologist; Ophthalmoscopy; Optical Coherence Tomography; Patients; Pediatric Hospitals; Pericytes; Phase; Photoreceptors; Population; Positioning Attribute; Publications; Recording of previous events; Reperfusion Therapy; Research; Research Personnel; Resolution; Retina; Retinal; Scanning; Scheme; Structure; System; Techniques; Technology; Testing; Tissues; Traction; Treatment Efficacy; United States National Institutes of Health; Vision; Vision research; adaptive optics; adaptive optics scanning laser ophthalmoscopy; base; clinical Diagnosis; clinical investigation; commercialization; design; disease diagnosis; early detection biomarkers; fundamental research; healthy volunteer; high resolution imaging; imager; imaging approach; imaging capabilities; imaging modality; imaging platform; improved; in vivo; instrument; multimodality; neurovascular; new technology; next generation; non-invasive imaging; novel; optical imaging; physical science; programs; prototype; retina blood vessel structure; retinal imaging; specific biomarkers; tool; treatment response; volunteer

Project Summary/Abstract There is currently a significant need for new non-invasive imaging techniques able to accurately quantify biomarkers for early detection, diagnosis, and quantification of complications in type 1 diabetes (T1D) such as diabetic retinopathy (DR). Physical Sciences Inc. (PSI) proposes to develop an imaging platform based on a new detection arrangement retrofitted to an existing high-resolution retinal imaging platform that includes adaptive optics-assisted scanning laser ophthalmoscopy (AO-SLO) and Optical Coherence Tomography (OCT). The new technique will allow for visualization and quantification of blood vessels structure and nerve bundle arrangement with exquisite details afforded by AO. The proposed detection scheme will be first tested and demonstrated using an existing multimodal AO retinal imager (MAORI) in Phase I and then in Phase II a new MAORI prototype will be developed specifically for imaging particular characteristics of retinal alterations induces by diabetes. Specific biomarkers for T1D complications will be defined based on patient data acquired by our collaborators from Boston Children's Hospital. About 40 patients with different stages of DR will be imaged during the Phase II Program. PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for the ophthalmic research market. PSI and our collaborators have recognized that one of the main impediments in developing a clinical market for AO-SLO's is that there have been few in-depth studies on the medical application of AO imagers for disease diagnosis and tracking the efficacy of treatments. Despite a relatively large number of research publications on the benefits of AO on understanding fundamental aspects of vision, so far AO has not gained traction in the clinical market. However, given the large incidence of neurovascular diseases, it is possible that the proposed application to use high- resolution retinal imaging to investigate the retinal changes due to diabetes will generate significant drive to bring AO closer to the clinical market. Therefore, PSI is requesting funding for developing this technology with a potentially significant impact on vision research and subsequently on the clinical diagnosis and management of DR.

项目摘要/摘要 目前，人们对能够准确的新非侵入成像技术非常需要 量化生物标志物，以早期检测，诊断和定量1型糖尿病的并发症 （T1D），例如糖尿病性视网膜病（DR）。物理科学公司（PSI）提议开发成像 基于对现有高分辨率视网膜成像改装的新检测布置的平台 包括自适应光学辅助扫描激光眼镜检查（AO-SLO）和光学的平台 相干断层扫描（OCT）。新技术将允许可视化和定量血液 船舶的结构和神经束布置，以及AO提供的精美细节。提议 检测方案将首先使用现有的多模式AO视网膜成像仪进行测试和证明 （毛利人）在第一阶段，然后在第二阶段中专门为成像开发新的毛利人原型 视网膜改变的特定特征是糖尿病引起的。 T1D的特定生物标志物 并发症将根据波士顿儿童的合作者获取的患者数据来定义 医院。在II期计划期间，将成像大约40名DR阶段不同的患者。 PSI在开发和商业化高分辨率视网膜成像器的历史上有悠久的历史 眼科研究市场。 PSI和我们的合作者已经意识到主要的 为AO-SLO开发临床市场的障碍是，很少有关于 AO成像器在疾病诊断和跟踪治疗功效中的医学应用。 尽管有关AO在理解上的好处的研究出版物相对较大 到目前为止，视觉的基本方面尚未在临床市场上获得关注。但是，给定 神经血管疾病的发生率很大，拟议的应用可能使用高 分辨率的视网膜成像调查糖尿病引起的视网膜变化将产生明显的驱动力 使AO更接近临床市场。因此，PSI要求为开发这项技术提供资金 可能对视力研究产生重大影响，随后对临床诊断和 博士管理